BioAdvance News Portfolio News Relmada Therapeutics

Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Europe Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms

By WebmasterJanuary 9, 2018November 1st, 2024No Comments

Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Europe Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms

See more here

Previous PostUCSF Medical Center selects Bainbridge Health to Support Its Continued Commitment to Medication Safety
Next PostVenatoRx Pharmaceuticals Receives Award for up to $16 Million from DTRA to Develop a Novel, First-in-Class Antibiotic as Countermeasure against Potential Drug-Resistant Biodefense Category A/B Respiratory Pathogens

Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Europe Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostUCSF Medical Center selects Bainbridge Health to Support Its Continued Commitment to Medication Safety

Next PostVenatoRx Pharmaceuticals Receives Award for up to $16 Million from DTRA to Develop a Novel, First-in-Class Antibiotic as Countermeasure against Potential Drug-Resistant Biodefense Category A/B Respiratory Pathogens